Results 21 to 30 of about 219,523 (189)

Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report [PDF]

open access: yesEndocrinology and Metabolism, 2013
Atypical antipsychotics have replaced conventional antipsychotics in the treatment of schizophrenia because they have less of a propensity to cause undesirable neurologic adverse events including extrapyramidal symptoms, tardive dyskinesia, and ...
Young Kyoung Sa   +9 more
doaj   +1 more source

Serum paraoxonase levels of schizophrenia patients treated with typical, atypical and combined antipsychotics

open access: yesPsychiatry and Clinical Psychopharmacology, 2021
Objective: Schizophrenia is a devastating disorder, starting in early adulthood and continuing with relapses and remissions. Prevalence of schizophrenia is 1% and the life expectancy of these patients is reduced.
Mehmet Akif Camkurt   +6 more
doaj  

The Effects of Atypical Antipsychotic Usage Duration on Serum Adiponectin Levels and Other Metabolic Parameters

open access: yesEurasian Journal of Medicine, 2019
Objective: Although atypical antipsychotics are well-tolerated and effective treatment options for schizophrenia, they have metabolic side effects, including weight gain and increased risk of Type II Diabetes Mellitus (DM).
Elif Oral   +5 more
doaj   +1 more source

Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study

open access: yes, 2014
Objective: Effects of conventional and atypical antipsychotics on bone mineral density (BMD) and serum prolactin levels (PRL) were examined in patients with schizophrenia.Methods: One hundred and sixty-three first-episode inpatients with schizophrenia ...
Mi, Guolin   +6 more
core   +1 more source

Atypical antipsychotics in the treatment of schizophrenia [PDF]

open access: yes, 2003
Over the last few years atypical antipsychotics have been used increasingly in the pharmacological treatment of schizophrenia. This review provides an overview of the pharmacological and clinical characteristics of atypical antipsychotics.
Bridler, R, Umbricht, D
core   +2 more sources

Evaluation of stroke risk associated with the use of typical or atypical antipsychotics among patients with cardiovascular diseases

open access: yesJournal of Medical Sciences, 2015
Background: Concerns regarding stroke safety associated with the use of atypical antipsychotics among dementia patients have been raised. Although observational studies have found conflicting associations of stroke risk with the use of typical or ...
Meng-Ting Wang   +5 more
doaj   +1 more source

Antipsychotics use in dementia: How safe are they?

open access: yesEuropean Psychiatry, 2021
Introduction Antipsychotics are frequently used for managing psychiatric and behavioral symptoms of dementia. However, it’s an off-label resource which remains controversial due to significant safety concerns in the elderly population, namely ...
C. Lopes
doaj   +1 more source

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia

open access: yesBiomedicines, 2023
Catalytic antibodies, or abzymes, are capable of not only binding but also hydrolyzing various proteins. Previously, an increase in the level of myelin basic protein (MBP)-hydrolyzing activity of antibodies was shown in patients with a number of ...
Daria A. Kamaeva   +6 more
doaj   +1 more source

Asenapine versus other atycipal antipsychotics for schizoaffective disorder Case study

open access: yesEuropean Psychiatry
Introduction Antipsychotics are psyschotropic medications that are indicated for the treatment of physchosis and mood disorders. Due to minimal side effects and their efficacy (affecting many receptors) compared to standard antipsychotics, today ...
E. Shaska
doaj   +1 more source

CLOZAPINE AND HALOPERIDOL INCREASE THE EXPRESSION OF PED/PEA-15: A PUTATIVE NOVEL MECHANISM FOR ANTIPSYCHOTIC-RELATED DIABETES [PDF]

open access: yes, 2008
Schizophrenia is a serious disorder that affects 1% of the population in the United States and Europe, and is associated with a significant reduction in life expectancy that approaches 20% compared with that of the general population.
Panariello, Fabio
core   +1 more source

Home - About - Disclaimer - Privacy